Title

Blood Levels of Local Anaesthetic in Hip Arthroplasty
Blood Levels of Local Anaesthetic in Hip Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Hip Arthroplasty
  • Phase

    N/A
  • Study Type

    Observational
  • Status

    Completed No Results Posted
  • Study Participants

    20
The primary goal is to evaluate ropivacaine blood concentrations during and after local anaesthetic (ropivacaine) infiltration - the Caledonian technique - for total hip replacement surgery. The investigators plan to measure these levels by testing blood samples taken over a timed period.

This will allow us to confirm whether the current regimen of local anaesthetic use is within safe limits.
Local anaesthetic (LA) toxicity may occur when the blood levels of a drug become particularly high. There is a need to confirm that the technique is safe to use. In addition, journal case reports may only describe serious side-effects of toxicity such as abnormal heart rhythms whilst more subtle clinical signs are rarely reported.

The investigators would like to study whether or not toxic levels may be approached in some patients or whether more subtle toxicity symptoms and signs are missed. For example, irregular heartbeat, low blood pressure or confusion/agitation.

Therefore, the investigators intend to study ropivacaine blood levels in patients receiving a total hip replacement in the Golden Jubilee National Hospital. A series of timed samples will be taken during the perioperative period. The anaesthesia and surgery will be performed as routine and no new treatment will be involved. Patient demographics, ropivacaine blood levels and clinical observations following LA administration will be collected.
Study Started
Aug 31
2012
Primary Completion
May 31
2013
Study Completion
May 31
2013
Last Update
Jun 05
2013
Estimate

Drug Ropivacaine

  • Other names: Naropin

Ropivacaine None

Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.

Population

Patients undergoing elective hip joint replacement where they will be receiving the Caledonian technique

Criteria

Inclusion Criteria:

Male or female patients greater than 65 years of age

Exclusion Criteria:

Patients with a known sensitivity/allergy to ropivacaine or amide-type local anaesthetics
Patients who are not suitable for the Caledonian technique
Patients who refuse or are unable to give consent
Patients undergoing bilateral hip replacements
Patients with known heart, liver or kidney failure
No Results Posted